CCCC — C4 THERAPEUTICS INC

Ownership history in WASATCH ADVISORS LP  ·  20 quarters on record

This page tracks every 13F SEC filing in which WASATCH ADVISORS LP reported a position in C4 THERAPEUTICS INC (CCCC). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.36% (2022 Q3)
Avg. % of fund
0.16%
First filed
2021 Q1
Last filed
2025 Q4
Quarters held
20
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 4,344,918 -507,823 -10.5% 0.05% $8.3M $1.91
2025 Q3 REDUCED 4,852,741 -2,571,921 -34.6% 0.06% $10.8M $2.22
2025 Q2 ADDED 7,424,662 +700,253 +10.4% 0.06% $10.6M $1.43
2025 Q1 ADDED 6,724,409 +651,808 +10.7% 0.06% $10.8M $1.60
16 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    CCCC price (monthly, adj. close)

Other funds also holding CCCC

As of 2025 Q4 — sorted by position size

Lynx1 Capital Management LP 3Y 2.74% Bain Capital Life Sciences Investors, LLC 3Y 7Y 1.05% SILVERARC CAPITAL MANAGEMENT, LLC 3Y 0.53% Soleus Capital Management, L.P. 3Y 0.27% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 0.16% INTREPID FAMILY OFFICE LLC 3Y 0.09% Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group 0.08% ORBIMED ADVISORS LLC 3Y 7Y 0.05% 683 Capital Management, LLC 3Y 7Y 0.03% Point72 Asset Management, L.P. 3Y 7Y 0.02%
← Back to WASATCH ADVISORS LP Holdings